Voyageur Pharmaceuticals Ltd.
VYYRF · OTC
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Revenue | $8 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $277 | $0 | $0 | $0 |
| Gross Profit | -$269 | $0 | $0 | $0 |
| % Margin | -3,346.4% | – | – | – |
| R&D Expenses | $384 | $54 | $40 | $106 |
| G&A Expenses | $0 | $320 | $630 | $294 |
| SG&A Expenses | $297 | $320 | $630 | $294 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $170 | $147 | $51 |
| Operating Expenses | $680 | $544 | $818 | $451 |
| Operating Income | -$949 | -$544 | -$818 | -$451 |
| % Margin | -11,818.8% | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | -$8 |
| Pre-Tax Income | -$949 | -$544 | -$818 | -$459 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$949 | -$544 | -$818 | -$459 |
| % Margin | -11,818.8% | – | – | – |
| EPS | -0.006 | -0.003 | -0.005 | -0.003 |
| % Growth | -67.6% | 35.8% | -60.6% | – |
| EPS Diluted | -0.006 | -0.003 | -0.005 | -0.003 |
| Weighted Avg Shares Out | 167,449 | 161,168 | 155,520 | 139,447 |
| Weighted Avg Shares Out Dil | 167,449 | 161,168 | 155,520 | 139,447 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$949 | -$544 | -$817 | -$458 |
| % Margin | -11,816.2% | – | – | – |